Skip to Content

STIL

This oligonucleotide microarray-based assay allows for the detection of exonic deletions or duplications of 105 genes currently tested in our laboratory. This is a custom designed array by Agilent technologies that contains ~140,000 probes present in a 4x180K format with probes more densely spaced in the exons of the genes being tested.  The array has been designed to detect copy number changes as small as 300-400 bp.  Single genes and custom panels of clinically related genes can be analyzed for deletions and duplications and results may be confirmed by qPCR, MLPA or alternative methodologies.

This assay will allow deletion/duplication analysis for disorders known to be caused by deletions or duplications within a single gene as well as for disorders for which the frequency of gene deletions/duplications is currently not well established. The array-CGH test is particularly indicated for disorders resulting from loss of function or haploinsufficiency. In addition, testing for exonic deletions/duplications is useful in autosomal recessive conditions in which only one mutation is identified by sequence analysis.  This assay will detect exonic deletions/duplications of the 105 genes on the array that may not be detected by whole genome array CGH.

Kumar et al (2009) reported three Indian families with MCPH that were homozygous for mutations in STIL [OMIM #181590]. STIL is necessary for proper mitotic spindle organization. To date no deletions or duplications involving the STIL gene as causative of microcephaly have been reported. STIL deletion/duplication analysis is available as an individual test or as part of the MCPH Tier 2 Deletion/Duplication Panel. Please see our information sheet for more details. 

Kumar, et al (2009) reported three Indian families with MCPH that were homozygous for mutations in STIL [OMIM #181590]. STIL is necessary for proper mitotic spindle organization. STIL sequencing analysis is available only as part of the MCPH Tier 2 Sequencing Panel.

Autosomal recessive primary microcephaly (MCPH) is characterized by: congenital microcephaly (3 SD below the mean at birth or at least 4 SD below the mean at later ages) mental retardation, but no other neurological findings (febrile or other mild seizures do not exclude the diagnosis) normal or mildly short stature that is less severe than the markedly small head circumference normal weight and appearance except for the microcephaly Mutations in the ASPM gene are the most common cause of MCPH.  Approximately 40% of patients (both consanguineous and non-consanguineous) with a strict diagnosis of MCPH have mutations in ASPM.  Several other genes, including CDK5RAP2, CENPJ, MCPH1, STIL, and CEP152 have been reported to cause MCPH in a small number of families. Our MCPH Tier 2 Sequencing Panel includes full gene sequencing for the ARFGEF2, CASC5, CDK5RAP2, CEP63, CEP135, CEP152, CENPJ, MCPH1, STIL, PNKP, WDR62, NDE1, SLC25A19, STAMBP and MED17 agenes. Our MCPH Tier 2 Deletion/Duplication Panel includes deletion/duplication analysis by array-CGH for 13 of the above listed genes (CASC5 and CEP135 deletion/duplication analysis not currently available). 

Contact The Foundation for Children with Microcephaly (www.childrenwithmicro.org) for more information and support.

Syndicate content

Newsletter

Join Our Mailing List
Email:
For Email Marketing you can trust